Compile Data Set for Download or QSAR
Report error Found 97 of affinity data for UniProtKB/TrEMBL: O90785
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514120(US11052087, Compound 14)
Affinity DataEC50:  6.54nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514108(US11052087, Compound 1)
Affinity DataEC50:  4.62nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514109(US11052087, Compound 2)
Affinity DataEC50:  56.6nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514111(US11052087, Compound 3)
Affinity DataEC50:  603nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514113(US11052087, Compound 4)
Affinity DataEC50:  5.71E+3nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514114(US11052087, Compound 5)
Affinity DataEC50:  1.14E+3nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514115(US11052087, Compound 6)
Affinity DataEC50:  278nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514116(US11052087, Compound 7)
Affinity DataEC50:  247nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514117(US11052087, Compound 8)
Affinity DataEC50:  102nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM514118(US11052087, Compound 9)
Affinity DataEC50:  20.6nMAssay Description:Compounds were tested in a high-throughput 384-well assay format for their ability to inhibit the replication of HIV-1 (IIIB) in MT-4 cells. Compound...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468574(US10806794, Compound mPEG7-NHCO-Saquinavir)
Affinity DataIC50: 0.0500nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468573(US10806794, Compound mPEG5-NHCO-Saquinavir)
Affinity DataIC50: 0.0500nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM50213021(CHEBI:63621 | Fortovase | Invirase | Ro-31-8959 | ...)
Affinity DataIC50: 0.0500nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468572(US10806794, Compound mPEG3-NHCO-Saquinavir)
Affinity DataIC50: 0.0700nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468568(US10806794, Compound mPEG1-OCONH-Tipranavir)
Affinity DataIC50: 0.188nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468563(US10806794, Compound mPEG5-O-Darunavir)
Affinity DataIC50: 0.210nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468567(US10806794, Compound mPEG0-OCONH-Tipranavir)
Affinity DataIC50: 0.292nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468564(US10806794, Compound mPEG7-O-Darunavir)
Affinity DataIC50: 0.358nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468366(US10806794, Compound mono-mPEG3-Atazanavir)
Affinity DataIC50: 0.366nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468570(US10806794, Compound mPEG5-OCONH-Tipranavir)
Affinity DataIC50: 0.462nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468562(US10806794, Compound mPEG3-O-Darunavir)
Affinity DataIC50: 0.475nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468569(US10806794, Compound mPEG3-OCONH-Tipranavir)
Affinity DataIC50: 0.617nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468560(US10806794, Compound mPEG5-N-Darunavir)
Affinity DataIC50: 1.10nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468557(US10806794, Compound mono-mPEG7-Atazanavir)
Affinity DataIC50: 1.29nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468372(US10806794, Compound mono-mPEG6-Atazanavir)
Affinity DataIC50: 1.31nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM8125(Darunavir (DRV) | CHEMBL1323 | (3R,3aS,6aR)-hexahy...)
Affinity DataIC50: 1.5nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468365(US10806794, Compound mono-mPEG1-Atazanavir)
Affinity DataIC50: 2.82nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468370(US10806794, Compound mono-mPEG5-Atazanavir)
Affinity DataIC50: 2.91nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468561(US10806794, Compound mPEG7-N-Darunavir)
Affinity DataIC50: 5.20nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468559(US10806794, Compound mPEG3-N-Darunavir)
Affinity DataIC50: 5.30nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586090(P3-P3' Entry 8)
Affinity DataIC50: 6nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM13934(CGP 73547 | CHEMBL1163 | methyl N-[(1S)-1-{[(2S,3S...)
Affinity DataIC50: 6.92nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM50479982(CHEBI:63628 | Aptivus | Tipranavir | U-140690 | US...)
Affinity DataIC50: 7.20nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586094(P3-P3' Entry 12)
Affinity DataIC50: 10nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586098(P3-P3' Entry 16)
Affinity DataIC50: 10nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586095(P3-P3' Entry 13)
Affinity DataIC50: 10nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586089(P3-P3' Entry 7)
Affinity DataIC50: 10nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586088(P3-P3' Entry 6)
Affinity DataIC50: 10nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586084(P3-P3' Entry 2)
Affinity DataIC50: 10nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM50067593(CHEBI:44032 | Crixivan | Indinavir | L-735524 | MK...)
Affinity DataIC50: 10.5nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468305(US10806794, Compound di-mPEG7-Atazanavir)
Affinity DataIC50: 10.9nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468566(US10806794, Compound mPEG7-amide-Tipranavir)
Affinity DataIC50: 12.2nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468300(US10806794, Compound di-mPEG3-Atazanavir)
Affinity DataIC50: 12.7nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586085(P3-P3' Entry 3)
Affinity DataIC50: 14nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468303(US10806794, Compound di-mPEG6-Atazanavir)
Affinity DataIC50: 15.6nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586083(P3-P3' Entry 1)
Affinity DataIC50: 17nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM468301(US10806794, Compound di-mPEG5-Atazanavir)
Affinity DataIC50: 17.3nMAssay Description:Protease inhibitors (PI) are used to treat HIV infection by preventing viral assembly and maturation through the inhibition of HIV-1 protease activit...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586086(P3-P3' Entry 4)
Affinity DataIC50: 19nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586091(P3-P3' Entry 9)
Affinity DataIC50: 20nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetHIV-1 protease(Human immunodeficiency virus)
Gilead Sciences

US Patent
LigandPNGBDBM586092(P3-P3' Entry 10)
Affinity DataIC50: 50nMpH: 5.6 T: 2°CAssay Description:Inhibition of HIV-protease activity for selected acids at P3-P3' positions. More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
Displayed 1 to 50 (of 97 total ) | Next | Last >>
Jump to: